Cassava Sciences settles SEC charges of ‘misleading’ Alzheimer’s trial claims
Sep 26, 2024
Shares of Cassava Sciences Inc. dropped more than 10% in the extended session Thursday after announcing a settlement with U.S. securities regulators, who had charged the pharma company and two former executives for “misleading claims” about an Alzheimer’s clinical trial.
https://www.marketwatch.com/story/cassava-sciences-settles-sec-charges-of-misleading-alzheimers-trial-claims-0edefa16?mod=mw_rss_topstories
Respond, make new discussions, see other discussions and customize your news...

To add this website to your home screen:

1. Tap tutorialsPoint

2. Select 'Add to Home screen' or 'Install app'.

3. Follow the on-scrren instructions.

Feedback
FAQ
Privacy Policy
Terms of Service